• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲基乙二醛抗乙型流感病毒感染的体外抗病毒活性评估

In vitro evaluation of the antiviral activity of methylglyoxal against influenza B virus infection.

作者信息

Charyasriwong Siriwan, Haruyama Takahiro, Kobayashi Nobuyuki

机构信息

Laboratory of Molecular Biology of Infectious Agents, Graduate School of Biomedical Sciences, Nagasaki University.

出版信息

Drug Discov Ther. 2016;10(4):201-10. doi: 10.5582/ddt.2016.01045. Epub 2016 Aug 23.

DOI:10.5582/ddt.2016.01045
PMID:27558282
Abstract

Influenza A and B virus infections are serious public health concerns globally. However, the concerns regarding influenza B infection have been underestimated. The currently used anti-influenza drugs have not provided equal efficacy for both influenza A and B viruses. Susceptibility to neuraminidase (NA) inhibitors has been observed to be lower for influenza B viruses than for influenza A viruses. Moreover, the emergence of resistance to anti-influenza drugs underscores the need to develop new drugs. Recently, we reported that methylglyoxal (MGO) suppressed influenza A virus replication in a strain-independent manner. Therefore, we hypothesize that MGO exhibits anti-influenza activity against B strains. This study aimed to evaluate the anti-influenza viral activity of MGO against influenza B strains by using Madin-Darby canine kidney (MDCK) cells. Several types of influenza B viruses were used to determine the activity of MGO. The susceptibilities of influenza A and B viruses to NA inhibitors were compared. MGO inhibited influenza B virus replication, with 50% inhibitory concentrations ranging from 23-140 μM, which indicated greater sensitivity of influenza B viruses than influenza A viruses. Our results show that MGO has potent inhibitory activity against influenza B viruses, including NA inhibitor-resistant strains.

摘要

甲型和乙型流感病毒感染是全球严重的公共卫生问题。然而,对乙型流感感染的关注一直被低估。目前使用的抗流感药物对甲型和乙型流感病毒的疗效并不相同。据观察,乙型流感病毒对神经氨酸酶(NA)抑制剂的敏感性低于甲型流感病毒。此外,抗流感药物耐药性的出现凸显了开发新药的必要性。最近,我们报道了甲基乙二醛(MGO)以菌株独立的方式抑制甲型流感病毒复制。因此,我们假设MGO对乙型流感病毒株具有抗流感活性。本研究旨在通过使用犬肾传代细胞(MDCK)来评估MGO对乙型流感病毒株的抗流感病毒活性。使用了几种乙型流感病毒来测定MGO的活性。比较了甲型和乙型流感病毒对NA抑制剂的敏感性。MGO抑制乙型流感病毒复制,50%抑制浓度范围为23 - 140μM,这表明乙型流感病毒比甲型流感病毒更敏感。我们的结果表明,MGO对乙型流感病毒具有强大的抑制活性,包括对NA抑制剂耐药的毒株。

相似文献

1
In vitro evaluation of the antiviral activity of methylglyoxal against influenza B virus infection.甲基乙二醛抗乙型流感病毒感染的体外抗病毒活性评估
Drug Discov Ther. 2016;10(4):201-10. doi: 10.5582/ddt.2016.01045. Epub 2016 Aug 23.
2
In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection.体外评估神经氨酸酶抑制剂和乙二醛对流感病毒感染的协同抑制作用。
Arch Med Res. 2015 Jan;46(1):8-16. doi: 10.1016/j.arcmed.2014.12.002. Epub 2014 Dec 15.
3
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.单个远离流感 B 病毒神经氨酸酶活性部位的 E105K 突变有助于降低对多种神经氨酸酶抑制剂药物的敏感性。
Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.
4
Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.流感 B 病毒神经氨酸酶单体-单体界面远离活性部位的突变降低了对神经氨酸酶抑制剂药物的敏感性。
J Infect Chemother. 2013 Oct;19(5):891-5. doi: 10.1007/s10156-013-0589-6. Epub 2013 Mar 26.
5
In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against clinical isolates of influenza virus in the Japanese 2012-2013 season.四种神经氨酸酶抑制剂对日本2012 - 2013年流感病毒临床分离株的体外神经氨酸酶抑制活性。
J Infect Chemother. 2015 Jan;21(1):39-42. doi: 10.1016/j.jiac.2014.08.030. Epub 2014 Sep 30.
6
Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.流感病毒神经氨酸酶抑制剂的表型药物敏感性测定
Clin Diagn Lab Immunol. 2004 Jan;11(1):21-8. doi: 10.1128/cdli.11.1.21-28.2004.
7
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.2009年甲型H1N1流感大流行病毒体外药敏的综合评估。
Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.
8
Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.2009-2010 年和 2010-2011 年流感季节日本大流行和季节性流感病毒的神经氨酸酶抑制剂敏感性特征。
Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.
9
Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities.具有强大体外抗流感病毒活性的环戊烷神经氨酸酶抑制剂。
Antimicrob Agents Chemother. 2001 Mar;45(3):743-8. doi: 10.1128/AAC.45.3.743-748.2001.
10
Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.2010 年和 2011 年中国乙型流感病毒的神经氨酸酶抑制剂敏感性检测发现对奥司他韦和扎那米韦敏感性降低的病毒。
Antiviral Res. 2013 Mar;97(3):240-4. doi: 10.1016/j.antiviral.2012.12.013. Epub 2012 Dec 23.

引用本文的文献

1
General Nutritional Profile of Bee Products and Their Potential Antiviral Properties against Mammalian Viruses.蜂产品的一般营养概况及其对哺乳动物病毒的潜在抗病毒特性。
Nutrients. 2022 Aug 30;14(17):3579. doi: 10.3390/nu14173579.
2
Recent progress in chemical approaches for the development of novel neuraminidase inhibitors.新型神经氨酸酶抑制剂开发的化学方法的最新进展。
RSC Adv. 2021 Jan 6;11(3):1804-1840. doi: 10.1039/d0ra07283d. eCollection 2021 Jan 4.
3
Emerging Glycation-Based Therapeutics-Glyoxalase 1 Inducers and Glyoxalase 1 Inhibitors.
新兴糖基化治疗学——醛糖还原酶 1 诱导剂和醛糖还原酶 1 抑制剂。
Int J Mol Sci. 2022 Feb 23;23(5):2453. doi: 10.3390/ijms23052453.
4
Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic?抗击新冠疫情第二波:蜂产品能帮助预防大流行吗?
Saudi J Biol Sci. 2021 Mar;28(3):1519-1527. doi: 10.1016/j.sjbs.2020.12.031. Epub 2020 Dec 22.
5
Prospects of honey in fighting against COVID-19: pharmacological insights and therapeutic promises.蜂蜜对抗COVID-19的前景:药理学见解与治疗前景
Heliyon. 2020 Dec;6(12):e05798. doi: 10.1016/j.heliyon.2020.e05798. Epub 2020 Dec 21.
6
Vulnerabilities of the SARS-CoV-2 Virus to Proteotoxicity-Opportunity for Repurposed Chemotherapy of COVID-19 Infection.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒对蛋白毒性的易感性——COVID-19感染的化疗药物重新利用机会
Front Pharmacol. 2020 Oct 9;11:585408. doi: 10.3389/fphar.2020.585408. eCollection 2020.
7
Potential of Methylglyoxal-Conjugated Chitosan Nanoparticles in Treatment of Fluconazole-Resistant Infection in a Murine Model.壳聚糖纳米颗粒与甲基乙二醛缀合物在治疗小鼠氟康唑耐药感染模型中的应用潜力。
Int J Nanomedicine. 2020 May 26;15:3681-3693. doi: 10.2147/IJN.S249625. eCollection 2020.
8
Kabirimine, a New Cyclic Imine from an Okinawan Dinoflagellate.卡比林胺,一种来自冲绳甲藻的新型环状亚胺。
Mar Drugs. 2019 Jun 13;17(6):353. doi: 10.3390/md17060353.
9
Identification of small molecule inhibitors for influenza a virus using in silico and in vitro approaches.利用计算机模拟和体外实验方法鉴定甲型流感病毒的小分子抑制剂。
PLoS One. 2017 Mar 8;12(3):e0173582. doi: 10.1371/journal.pone.0173582. eCollection 2017.